<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601235</url>
  </required_header>
  <id_info>
    <org_study_id>NMDEMS0214NA-III</org_study_id>
    <nct_id>NCT02601235</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pediatric Drugs in Nasal Congestion</brief_title>
  <official_title>Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the Naridrin in improving nasal&#xD;
      congestion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, multicenter clinical study. Maximal experiment duration: 2 days; 2&#xD;
      visits. Safety and efficacy evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Actual">April 3, 2019</completion_date>
  <primary_completion_date type="Actual">August 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of Nasal Congestion</measure>
    <time_frame>2 days</time_frame>
    <description>Relief of nasal congestion will be measured on a scale of 0 to 3 (0 = without congestion and 3 total congestion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 days</time_frame>
    <description>Safety of the drug will be assessed by observation of adverse events monitored for the type, frequency and intensity during the days of the follow-up.&#xD;
The evaluation of the heart frequency will also be a safety parameter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Nasal Congestion</condition>
  <arm_group>
    <arm_group_label>Naridrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naridrin: 2 drops in each nostril once daily as prescription</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05 % Oxymetazoline Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 pumps in each nostril every 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naridrin</intervention_name>
    <description>Naridrin® : 2 drops in each nostril once daily as prescription</description>
    <arm_group_label>Naridrin</arm_group_label>
    <other_name>Naphazoline Hydrochloride</other_name>
    <other_name>Mepyramine Maleate</other_name>
    <other_name>Dexpanthenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afrin</intervention_name>
    <description>2 pumps in each nostril every 12 hours.</description>
    <arm_group_label>0.05 % Oxymetazoline Hydrochloride</arm_group_label>
    <other_name>oxymetazoline hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged 10-17 years old with clinical symptoms of inflammatory of allergic&#xD;
             nasal congestion in at least one nostril due to rhinitis or rhinopharyngitis (cold or&#xD;
             flu);&#xD;
&#xD;
          -  Signed Consent;&#xD;
&#xD;
          -  Participants whose mother, father and / or legal guardian is in accordance with all&#xD;
             study purposes and procedures;&#xD;
&#xD;
          -  Participants with clinical symptoms of nasal congestion in at least one nostril&#xD;
             diagnosed through the Glatzel mirror;&#xD;
&#xD;
          -  Participants with minimal score of 2 points in the 0 to 3 scale (Moderate&#xD;
             obstruction).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in clinical trial in the year prior to this study;&#xD;
&#xD;
          -  Total obstruction of one of the nostrils by other etiologies that are not inflammatory&#xD;
             or allergic;&#xD;
&#xD;
          -  Infectious bacterial-disease (clinically diagnosed);&#xD;
&#xD;
          -  Participants treated with antibiotic or possible antibiotic use due to another medical&#xD;
             condition;&#xD;
&#xD;
          -  Use of intranasal corticosteroids (7 days prior to the study) or systemic (15 days&#xD;
             prior to the study), regarding the plasma half-life of the drug;&#xD;
&#xD;
          -  Use of decongestants or antihistamine (intranasal or systemic) in the 03 days prior to&#xD;
             the study;&#xD;
&#xD;
          -  Use of inhaled drugs (except nasal moisturizers such as saline solution) or treatment&#xD;
             with immunosuppressants in the week before the study;&#xD;
&#xD;
          -  Participants with septum deviation grade II and III, nasal polyps, severe turbinate&#xD;
             hypertrophy, adenoid hypertrophy, or other determining factors for nasal obstruction;&#xD;
&#xD;
          -  History of hyperthyroidism or hypertension;&#xD;
&#xD;
          -  History of hypersensitivity to the components of the study drugs;&#xD;
&#xD;
          -  History of transphenoidal hypophysectomy or oronasal surgery with exposure of the&#xD;
             dura-mater;&#xD;
&#xD;
          -  Exclusive mouth-breathers patients;&#xD;
&#xD;
          -  Participants in chronic drug treatment for allergies (eg vaccines for allergy,&#xD;
             cromolyn);&#xD;
&#xD;
          -  History of alcohol and / or drug abuse 3 months prior to the study;&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy and lactating patients;&#xD;
&#xD;
          -  PAny clinical, laboratory that, in the judgment of the investigator, may interfere&#xD;
             with the safety of research participants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal congestion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrilamine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Naphazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

